# psoriasis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 5
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3982
- Completion tokens: 24806
- Reasoning tokens: 
- Total tokens: 28788
- API requests reported: 
- Elapsed seconds: 233.363
- Final benchmark system: raw; file rank 4/5; original repeat 5; model vendor: DeepSeek

---
## Interpretation of Psoriasis Lesional Skin vs Normal Skin Transcriptome

All statistical evidence is derived from the supplied differential expression table. Effect sizes are log2 fold changes; no prognostic hazard ratios were provided, so all interpretations are disease-state oriented.

---

## 1. Overall biological interpretation

The psoriatic lesion transcriptome is dominated by a coordinated, extremely strong upregulation of epidermal keratinocyte-derived inflammatory mediators, antimicrobial peptides/alarmins, cornified-envelope components, and lipid-metabolizing enzymes. This pattern is consistent with the established model of psoriasis as a disease of IL-17/IL-23-driven keratinocyte activation, in which keratinocytes themselves become amplifiers of inflammation.

The most biologically coherent signal is **IL-36/IL-20 cytokine overexpression**, combined with **massive induction of antimicrobial and alarmin genes**, and **marked remodeling of epidermal differentiation/barrier genes**. The simultaneous upregulation of negative regulators such as IL36RN, TNIP3, ZC3H12A, and CD274 indicates that the lesion is not simply a pro-inflammatory state, but an actively counter-regulated inflammatory process.

The downregulated gene set is smaller and less functionally interpretable. It includes BTC, CYP2W1, UGT3A2, SAPCD1, and several noncoding transcripts. These may reflect loss of a subset of normal keratinocyte metabolic/differentiation features, but the evidence is insufficient to define a robust separate biological program.

---

## 2. Core biological programs

### Program 1: IL-36/IL-20 family cytokine-driven inflammation
- **Direction**: Upregulated in lesional skin.
- **Supporting genes**: IL36A, IL36G, IL36RN, IL19, IL20, IL26, IRAK2, TNIP3, ZC3H12A, PRKCQ
- **Pathway**: KEGG “Cytokine-cytokine receptor interaction”; Reactome “Interleukin-36 family signaling”; Reactome “Interleukin-20 family signaling”; Hallmark “IL6_JAK_STAT3_SIGNALING”
- **Interpretation**: IL36A and IL36G are keratinocyte-derived IL-36 agonists with strong pro-inflammatory activity. IL19, IL20, and IL26 belong to the IL-20 subfamily and signal through receptors that activate STAT3, promoting keratinocyte proliferation and epidermal hyperplasia. IRAK2 is downstream of IL-1 receptor/TLR signaling, while TNIP3 and ZC3H12A are inducible negative regulators of NF-κB and inflammatory mRNA stability. The co-upregulation of agonists and feedback inhibitors suggests an active but partially self-limiting inflammatory loop.
- **Strength and limitations**: Strong statistical signal from multiple independent genes. However, bulk tissue does not identify the cell source; IL26 may be T-cell-derived, while IL36A/G are likely keratinocyte-derived. The net biological activity depends on protein-level agonist/antagonist balance, not transcript abundance alone.

### Program 2: Antimicrobial peptide/alarmin response and neutrophil/myeloid infiltration
- **Direction**: Upregulated in lesional skin.
- **Supporting genes**: DEFB4A, DEFB4B, DEFB103A, DEFB103B, S100A7, S100A7A, S100A8, S100A12, PI3, CXCR2, HPSE
- **Pathway**: GO “Antimicrobial humoral response”; Reactome “Antimicrobial peptides”; KEGG “IL-17 signaling pathway”; KEGG “Chemokine signaling pathway”
- **Interpretation**: Beta-defensins and S100 alarmins are massively induced. S100A7/psoriasin and S100A7A are keratinocyte-derived antimicrobial proteins; S100A8 and S100A12 are calgranulins/alarmins with potent chemoattractant and DAMP activity. CXCR2 is a major neutrophil chemokine receptor, and HPSE can facilitate leukocyte extravasation by degrading heparan sulfate. Together, these genes likely account for the neutrophil-rich infiltrates and altered cutaneous antimicrobial defense classically seen in psoriasis.
- **Strength and limitations**: Very large effect sizes and multiple gene families. A major limitation is that S100A8/A12 and CXCR2 may partly originate from infiltrating neutrophils rather than keratinocytes, so cell-composition effects cannot be excluded.

### Program 3: Aberrant keratinocyte differentiation and cornified-envelope remodeling
- **Direction**: Upregulated in lesional skin.
- **Supporting genes**: KRT6A, SPRR2A/B/D/E/F/G, SPRR3, LCE3A, LCE3D, GJB2, GJB6, SERPINB3, SERPINB4, SERPINB11, SERPINB13, KLK13, PI3
- **Pathway**: GO “Keratinocyte differentiation”; GO “Cornified envelope”; Reactome “Formation of the cornified envelope”
- **Interpretation**: Psoriatic keratinocytes undergo a regenerative/differentiation switch, marked by induction of KRT6A, small proline-rich proteins, late cornified envelope proteins, connexins, and squamous differentiation-associated serpins. The co-expression of structural envelope proteins and proteases/protease inhibitors suggests an altered epidermal barrier with abnormal desquamation and remodeling. This aligns with the histological features of acanthosis, parakeratosis, and loss of normal terminal differentiation.
- **Strength and limitations**: Strong multi-gene support and direct relevance to epidermal pathology. However, the exact balance between barrier repair and pathological differentiation cannot be determined from transcript data alone.

### Program 4: Lipid/eicosanoid and keratinocyte metabolic reprogramming
- **Direction**: Upregulated in lesional skin.
- **Supporting genes**: PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5, KYNU
- **Pathway**: KEGG “Arachidonic acid metabolism”; GO “Lipid metabolic process”; KEGG “PPAR signaling pathway”
- **Interpretation**: PLA2G4D/E are phospholipases that can release arachidonic acid, the precursor of pro-inflammatory eicosanoids such as PGE₂ and LTB₄. AKR1B10 and AKR1B15 are aldo-keto reductases involved in retinoid and lipid aldehyde metabolism; AKR1B10 can deplete retinoic acid, thereby potentially promoting keratinocyte proliferation. FABP5 transports fatty acids to nuclear receptors and may support PPAR-driven metabolic activation. KYNU is part of tryptophan/kynurenine metabolism, which can modulate immune responses. These changes point to a broader metabolic rewiring that supports inflammation and hyperproliferation.
- **Strength and limitations**: Multiple enzymes converge on lipid/inflammatory metabolism. However, the functional connection between these genes is indirect, and lipidomic/metabolomic validation is required.

### Program 5: Counter-regulatory and immune checkpoint negative feedback
- **Direction**: Upregulated in lesional skin.
- **Supporting genes**: IL36RN, TNIP3, ZC3H12A, CD274
- **Pathway**: GO “Negative regulation of inflammatory response”; GO “Negative regulation of NF-κB transcription factor activity”; Reactome “PD-1 signaling”
- **Interpretation**: Alongside pro-inflammatory signals, the lesion strongly induces several negative regulators. IL36RN encodes the IL-36 receptor antagonist; TNIP3 inhibits NF-κB signaling; ZC3H12A/regnase-1 destabilizes inflammatory mRNAs; and CD274/PD-L1 suppresses T-cell responses. This pattern likely represents negative feedback that limits tissue damage and may explain the chronic, relapsing rather than explosive nature of plaque psoriasis.
- **Strength and limitations**: Multiple independent negative regulators with known functions support this interpretation. The main limitation is that these genes may be secondary consequences of inflammation rather than primary drivers, and their induction cannot be interpreted as an effective protective program without functional data.

---

## 3. Key genes and interaction modules

### 1. IL-36 module: IL36A, IL36G, IL36RN
- **Direction**: All upregulated; IL36A log2FC 11.37, IL36G 5.68, IL36RN 3.00.
- **Role**: IL-36 cytokines are key amplifiers of the IL-17/IL-23 axis; IL36RN is the natural receptor antagonist.
- **Gene-gene relationship**: IL36A/G are agonists and IL36RN is an antagonist at the IL-36 receptor complex. This is a direct receptor-level relationship, but the bulk RNA data only support co-expression and pathway co-membership.

### 2. IL-20 family module: IL19, IL20, IL26
- **Direction**: All upregulated; IL19 7.58, IL20 5.67, IL26 4.36.
- **Role**: IL-20 subfamily cytokines activate STAT3 and promote keratinocyte proliferation and epidermal hyperplasia.
- **Gene-gene relationship**: These cytokines share receptor components, particularly IL20RA/IL20RB-dependent signaling. They are pathway co-members, not direct interaction partners.

### 3. S100 alarmin module: S100A7, S100A7A, S100A8, S100A12
- **Direction**: All upregulated; S100A7 7.09, S100A7A 9.83, S100A8 7.73, S100A12 8.33.
- **Role**: Antimicrobial peptides and danger-associated molecular patterns that recruit neutrophils and activate innate immune responses.
- **Gene-gene relationship**: S100A8 and S100A12 are known to form oligomeric complexes; S100A8 can heterodimerize with S100A9, which is not in this dataset. S100A7 and S100A7A are distinct proteins. Direct physical interactions among all four are not established from these data.

### 4. Beta-defensin module: DEFB4A, DEFB4B, DEFB103A, DEFB103B
- **Direction**: All upregulated; DEFB4A 11.18, DEFB4B 11.03, DEFB103A/B ~5.75.
- **Role**: Antimicrobial peptides with chemotactic and immunomodulatory activity.
- **Gene-gene relationship**: They are encoded in β-defensin genomic clusters and are co-expressed. No direct physical interaction among these peptides is supported by this dataset.

### 5. Cornified-envelope/epidermal differentiation module: SPRR2A/B/D/E/F/G, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6
- **Direction**: All upregulated.
- **Role**: Reflect altered keratinocyte differentiation, hyperproliferation, and barrier remodeling.
- **Gene-gene relationship**: SPRR and LCE proteins are substrates for transglutaminase-mediated crosslinking during cornified-envelope assembly. This is a known direct biochemical interaction at the protein level, but the RNA data only provide co-expression evidence.

### 6. Protease/anti-protease module: KLK13, TMPRSS11D, PRSS27, HABP2, PI3, SERPINB3/4/11/13
- **Direction**: All upregulated.
- **Role**: Proteases and serpins likely regulate epidermal desquamation, barrier remodeling, and inflammation.
- **Gene-gene relationship**: Serpins inhibit proteases, but specific direct pairing between the particular proteases and serpins in this dataset is not established. The relationship should be considered a co-expressed protease-antiprotease network hypothesis.

### 7. Lipid/eicosanoid module: PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5
- **Direction**: All upregulated.
- **Role**: Phospholipase-mediated arachidonic acid release, eicosanoid production, retinoid metabolism, and fatty acid signaling.
- **Gene-gene relationship**: Pathway co-members in lipid metabolism; no direct physical interactions are inferred.

### 8. Immune infiltration module: CXCR2, CXCL13, HPSE
- **Direction**: All upregulated; CXCR2 2.70, CXCL13 5.89, HPSE 2.92.
- **Role**: CXCR2 supports neutrophil chemotaxis; CXCL13 recruits B cells/follicular T cells; HPSE degrades heparan sulfate and facilitates leukocyte migration.
- **Gene-gene relationship**: CXCL13 binds CXCR5, not CXCR2, so these are not direct ligand-receptor partners. They are co-expressed mediators of different leukocyte recruitment pathways.

### 9. Counter-regulatory module: TNIP3, ZC3H12A, CD274
- **Direction**: All upregulated; TNIP3 7.28, ZC3H12A 3.85, CD274 3.44.
- **Role**: Negative regulation of NF-κB, inflammatory mRNA stability, and T-cell activation.
- **Gene-gene relationship**: TNIP3, ZC3H12A, and CD274 are independent negative regulators. CD274 directly binds PD-1 on T cells; TNIP3 acts in the A20/NF-κB network; ZC3H12A targets mRNAs. These are regulatory rather than direct physical interactions among the three genes.

---

## 4. Validation priorities

### 1. Mechanistic hypothesis: IL-36/IL-20 axis drives keratinocyte inflammation and differentiation
- **Why prioritized**: This is the most coherent pro-inflammatory program and connects multiple top genes.
- **Current dataset evidence**: Strong co-upregulation of IL36A/G, IL19/20/26, and downstream inflammatory/barrier genes.
- **External evidence**: IL-36 blockade is clinically relevant in pustular psoriasis; IL-20 family cytokines are known to activate STAT3 in keratinocytes.
- **Next step**: Use 3D keratinocyte organotypic cultures stimulated with IL-36α/γ and IL-19/20/26; test IL36R or IL20R blockade; measure S100, DEFB4, SPRR, and KRT6A responses.
- **Conclusion status**: Supported hypothesis, not established causation.

### 2. Therapeutic target: PLA2G4D/eicosanoid/AKR1B10 metabolic node
- **Why prioritized**: Lipid metabolism is a potentially druggable node and less well studied than the cytokine axis.
- **Current dataset evidence**: Coordinated upregulation of PLA2G4D/E, AKR1B10/15, and FABP5.
- **External evidence**: Arachidonic acid/eicosanoid pathways are long-standing candidates in psoriasis; AKR1B10 is overexpressed in psoriatic epidermis.
- **Next step**: Knock down or inhibit PLA2G4D or AKR1B10 in psoriatic keratinocyte models; measure eicosanoids, retinoic acid levels, and proliferation.
- **Conclusion status**: Exploratory hypothesis. Drug availability alone does not establish therapeutic relevance.

### 3. Biomarker: S100A8/A12, DEFB4, IL36G as lesional/severity biomarkers
- **Why prioritized**: These are among the most strongly upregulated genes and are potentially measurable in tissue, tape strips, or serum.
- **Current dataset evidence**: Extremely large effect sizes with very low FDR.
- **External evidence**: Calgranulins and defensins have been detected in psoriatic plaques and body fluids.
- **Next step**: Validate in an independent cohort using quantitative RT-PCR/protein assays, and test correlation with Psoriasis Area and Severity Index and treatment response.
- **Conclusion status**: Supported hypothesis for association; not yet an established clinical biomarker.

### 4. Interaction/network hypothesis: SERPINB/elafin and KLK/serine protease balance
- **Why prioritized**: The coordinated upregulation of proteases and protease inhibitors suggests an important but under-characterized regulatory network.
- **Current dataset evidence**: Co-upregulation of KLK13, TMPRSS11D, PRSS27, HABP2, PI3, and SERPINB3/4/11/13.
- **External evidence**: Kallikrein/serpin cascades regulate desquamation in skin; elafin/SERPINs are induced in inflammatory skin.
- **Next step**: Test direct inhibition of specific KLKs or TMPRSS11D by SERPINB3/4 or PI3 using recombinant proteins and protease assays; perturb in keratinocyte differentiation models.
- **Conclusion status**: Exploratory hypothesis.

### 5. Confounding/composition check: single-cell and spatial resolution of cell-type contributions
- **Why prioritized**: Bulk skin transcriptomes reflect keratinocytes, neutrophils, T cells, B cells, dendritic cells, and fibroblasts. Many key signals may be driven by infiltrating immune cells rather than keratinocyte-intrinsic changes.
- **Current dataset evidence**: Strong expression of S100A8/A12, CXCR2, CXCL13, and IL26, which are likely immune-cell-enriched.
- **External evidence**: Known cell-type distributions: S100A8/A12 and CXCR2 in myeloid/neutrophil populations; CXCL13 in T/B cells; SPRR/LCE/KRT6A in keratinocytes.
- **Next step**: Perform single-cell or spatial transcriptomics on matched lesional/non-lesional/normal skin; use deconvolution on bulk data; confirm protein localization by multiplex immunohistochemistry.
- **Conclusion status**: Required interpretation check; existing conclusions should be considered provisional until cell composition is accounted for.

---

## 5. Evidence grounding

- **Direct input evidence**: The differential expression statistics provide extremely strong evidence that the listed genes are altered in bulk lesional psoriatic skin. However, they do not establish cell source, protein abundance, or causality.
- **Pathway/ontology evidence**: The genes cluster in known inflammatory, antimicrobial, cornified-envelope, and lipid metabolism pathways. This supports program-level interpretation but is not independent of prior literature.
- **Protein interaction/regulatory evidence**: IL36RN antagonism of IL-36 receptors, CD274/PD-1 binding, S100A8/S100A9 complex formation, and transglutaminase-mediated crosslinking of SPRR/LCE are known biochemical mechanisms. These are external to the input data and should not be inferred from RNA co-expression alone.
- **Disease-association evidence**: Several genes have strong prior psoriasis associations, including IL36RN mutations in pustular psoriasis, LCE3C_LCE3B deletion as a psoriasis risk factor, and β-defensin copy-number variation. This external genetic evidence supports relevance but is partly independent of the current transcriptomic results.
- **Expression/tissue evidence**: Keratinocyte-enriched genes such as SPRR, LCE, KRT6A, and SERPINB3/4 are consistent with epidermal pathology. Immune-cell-enriched genes such as CXCR2, CXCL13, and possibly S100A8/A12 highlight the need to separate immune infiltrate from keratinocyte-intrinsic signals.
- **Drug/therapeutic evidence**: Existing effective therapies targeting IL-17/IL-23 and emerging IL-36 pathway modulators support the general importance of these inflammatory circuits. They do not validate any specific gene in this dataset as a therapeutic target.

The input expression data and external pathway/disease knowledge are not fully independent because much of the pathway annotation and prior disease literature derive from overlapping experiments. The strongest independent anchors are the coordinated magnitude of expression change within multiple gene families and the known cell-type biology of the skin.

---

## 6. Limitations and alternative explanations

### 1. Cell-composition differences
Lesional psoriatic skin contains more keratinocytes, neutrophils, T cells, and dendritic cells than normal skin. Apparent upregulation of immune-cell-enriched genes may reflect increased infiltrate rather than increased per-cell expression. This is especially relevant for S100A8/A12, CXCR2, CXCL13, and IL26. **Investigation**: single-cell/spatial transcriptomics, flow cytometry, and immunostaining.

### 2. Disease severity, treatment exposure, and clinical heterogeneity
No clinical metadata were provided. Disease severity, treatment history, lesion age, and genetic background can strongly influence the transcriptome. The same gene could be upregulated in untreated severe lesions but not in mild or treated lesions. **Investigation**: validation in a clinically annotated cohort with paired lesional, non-lesional, and normal skin.

### 3. Technical and normalization issues
Only summary statistics were available. Large log2FC values may be inflated for genes with very low baseline expression in normal skin (e.g., antimicrobial peptides). Pseudogenes and unannotated loci such as VNN3P, LOC105376238, and CERNA2 should be interpreted with caution. **Investigation**: inspect raw counts, platform, normalization, and mapping quality.

### 4. Association-versus-causation and feedback confounders
Upregulation of negative regulators such as IL36RN, TNIP3, ZC3H12A, and CD274 may be reactive to inflammation rather than disease-driving. The co-expression of IL-36 agonists and antagonist makes net pathway activity impossible to infer from transcript data alone. **Investigation**: functional perturbation studies and measurement of protein-level activity.

### 5. Broad pathway enrichment and literature bias
Many top genes are well-known psoriasis markers, so pathway-level interpretations may be biased toward previously studied biology. Conversely, the many uncharacterized noncoding transcripts may hide novel mechanisms, but their roles cannot be assigned from expression data alone. **Investigation**: unbiased functional screens and targeted follow-up of reproducible, uncharacterized transcripts.

---

Overall, the current data provide strong transcriptomic evidence for an IL-36/IL-20-driven, keratinocyte-centered inflammatory program with massive antimicrobial/alarmin activation and epidermal barrier remodeling. The major caveat is that bulk tissue composition and lack of functional validation prevent causal conclusions.
